SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Bausch Health Companies Inc.

SG&A Efficiency: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. This analysis compares the SG&A efficiency of Exelixis, Inc. and Bausch Health Companies Inc. over the past decade.

Bausch Health Companies Inc.

Bausch Health has consistently maintained high SG&A expenses, peaking at approximately $2.9 billion in 2023. Despite fluctuations, their expenses have grown by about 44% since 2014, reflecting their expansive operations and market reach.

Exelixis, Inc.

In contrast, Exelixis, Inc. has shown a remarkable increase in SG&A expenses, rising from $51 million in 2014 to $543 million in 2023, a tenfold increase. This growth signifies their aggressive expansion and investment in market presence.

Conclusion

While Bausch Health's expenses indicate stability, Exelixis's rapid increase suggests a strategic push for growth. Understanding these trends is vital for investors and stakeholders aiming to gauge the financial strategies of these companies.